Skip to content

The Lack of Clinical Trials in the Medical Marijuana Industry

The Lack of Clinical Trials in the Medical Marijuana Industry

As time goes on, medical marijuana is starting to break barriers in various states across the country. Out of the 50 states, 33 have approved a comprehensive medical marijuana program (NCSL). Currently, marijuana, medical or recreational, is illegal at the federal level, despite legalization in various states. Many medical professionals are interested in prescribing medical marijuana to patients with a qualifying condition, but most feel they don’t have sufficient knowledge or feel comfortable to do so. This lack of knowledge is a direct result of the lack of clinical trials in the medical marijuana industry, but why is that the case?

The Problem

The biggest problem surrounding why it’s so difficult for scientists to get clinical trials up and running is the continuation of roadblocks that federal laws create. Even though medical marijuana may be legalized in some states, scientists are still having a significantly harder time conducting research on the medicinal benefits of this “illicit drug”. Without sufficient research, we can expect the legalization of marijuana at the federal level, even for medicinal uses, to be a steep uphill battle.

Under federal law, cannabis is on the same level as controlled substances, like cocaine and heroin. Every controlled substance is classified by schedule based on relative potential for abuse and medicinal value. Under the CSA, cannabis is classified as a Schedule 1 drug, meaning the federal government views cannabis as highly addictive and having no medical value. (SafeAccessNow.org)

These strict federal laws can make it more difficult for researchers to legally obtain the necessary supply of marijuana for their trials. The difficulty of obtaining a legal supply puts any planned research at a hard stop with no chance of moving forward. Essentially, we’re currently experiencing a catch-22, with the federal government refusing to legalize marijuana based on its Schedule 1 standing and the need to obtain marijuana legally for clinical trials to prove this view unsound.

In fact, if one were to conduct a clinical trial, they would have an easier time conducting research on drugs such as ecstasy or magic mushrooms. Clinical researchers can request the ability to grow or create restricted compounds, including LSD, MDMA or psilocybin, in their lab from the DEA. Unfortunately, this is not the case with cannabis.

As expected, these classifications and restrictions on marijuana are causing a variety of frustrations across the medical community. Many researchers have noted that research is “hindered by a complicated federal approval process, limited availability of research grad marijuana and the debate over legalization.” (SafeAccessNow.org) Although we have these restrictions by the federal government, scientists are still working towards the ability to conduct sufficient research on marijuana and will continue their efforts as much as possible while following the law.

What’s an Alternative?

Since it can be difficult to locate information about the safety and effect of cannabis on the human body, how are physicians supposed to know if prescribing medical marijuana is right for their patients? Enter: Arfinn Med. Many physicians who believe in the therapeutic power of medical marijuana are beginning to try alternative treatment plans with their patients. Arfinn Med provides a portal for these physicians to track and store data to be analyzed. Additionally, physicians have the ability to consult and connect with a nationwide network of medical professionals to discuss actual experiences regarding patient outcomes.

If you are a licensed medical professional and interested in gaining more data on medical marijuana or and what it can do for your patients, join Arfinn Med for FREE today! Let us help you start treating your patients with the power of data on your side.  

Sources: http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx

https://www.safeaccessnow.org/federal_marijuana_law

https://www.safeaccessnow.org/medical_cannabis_research_what_does_the_evidence_say

https://www.cmcr.ucsd.edu/

Stories you may be interested in

Substance in cannabis ‘could boost pancreatic cancer treatments’

A substance found in cannabis plants might boost treatments for patients with pancreatic cancer, research in mice has suggested. Cannabidiol, or CBD, is not psychoactive, meaning it does not produce feelings of being high in those who take it. It is extracted from hemp plants and is legal in the UK, although a CBD product…
Read More

Doctors and patients are flying blind as medical marijuana use rises, research lags

Marijuana’s role in the health care universe has grown exponentially over the past few years. Currently, 33 U.S. states have legalized the use of medical marijuana, and more and more states are considering making it legal for recreational purposes as well. As cannabis becomes more accessible, many people are turning to tetrahydrocannabinol (THC) and cannabidiol (CBD) products to…
Read More

Data Migration During EMR Changes

One of the most challenging aspects when deciding to switch to a new EMR system is how to get existing data from the old system to the new system safely, securely and accurately.  Many times, the scope of this task is enough to force providers to remain with a subpar vendor even though there are…
Read More

COVID-19 and medical cannabis patients: What you need to know

In the midst of the COVID-19 maelstrom, the recent shuttering of nonessential stores has created concern around access to cannabis, particularly for medicinal cannabis consumers. Those who depend on cannabis for therapeutic purposes will be relieved to learn that across the US, medical cannabis dispensaries have been deemed essential services, comparable to pharmacies. As of March…
Read More

Are You Prepared For Questions About Medical Cannabis?

With over 85% of Americans supporting legalizing medical cannabis, it’s inevitable that patients will begin asking their primary care doctors about its use and overall efficacy. Doctors and other medical professionals will be called upon to be ‘sense-makers’ for a treatment they never studied in medical school and have limited available research to draw upon. …
Read More

July Updates

In our quest to save medical marijuana clinics valuable time, Arfinn Med has continued to release new functionality that improves EMR workflows.  This has led to the development of our new telehealth platform, new automated patient intake emails, and generating all state required documentation.  Continuing on our quest, we are proud to release our new…
Read More